Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242760 · ClinicalTrials.gov registry record · Phase 2
P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
A Phase 2 study, sponsored by Novan.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
NCT02242760 is a Phase 2 study that has completed, run by Novan. The registered enrollment target is 213 participants.
The verdict
NCT02242760, a Phase 2 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
Study Summary
This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.
Interventions
- DRUG Vehicle Gel
- DRUG SB204 4%
- DRUG SB204 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02242760
The ClinicalTrials.gov registry entry for NCT02242760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle Gel is the first listed.
NCT02242760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02242760 about?
NCT02242760 is a clinical study titled "P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris". This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.
What is the current status of trial NCT02242760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2014-11. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02242760?
The interventions under investigation include: Vehicle Gel (DRUG), SB204 4% (DRUG), SB204 2% (DRUG).
Who is sponsoring clinical trial NCT02242760?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.